Fernando Martinez Estrada
Honorary Departmental Senior Research Associate
I am a Senior research Associate in Macrophage pathobiology. I am originally from Havana-Cuba, where I graduated as Biochemist to then pursue a doctorate in Molecular Medicine and Immunology in Milan-Italy; I then joined Oxford University.
My main objectives in science are to understand how macrophages participate in disease pathogenesis and to identify new avenues to interfere with their deleterious properties. Macrophages are present in all tissues, numerous, and their role in inflammation is primarily controlled by modulation of their gene and protein repertoire. The transcriptome of macrophages holds the key to the fundamental question in macrophage pathobiology and inflammatory medicine: how to inactivate and reprogramme the macrophage.
My areas of expertise are macrophage cellular and systems biology (isolation-culture, gene and proteomic signatures, microarrays, proteomics, functional analysis), regulation of macrophage activation, and modern pathology. I use techniques to complement my transcriptome work, including conventional histological techniques, and modern developments such as multiple immunofluorescence histology, multiple FACS staining and Cytof. The application of the knowledge that I derive with my tools, allows re interpretation of conventional paradigms and proposals of new ways of understanding disease and potential treatments.
Martinez FO. and Gordon S., (2014), F1000prime reports, 6
Martinez FO. et al, (2013), Blood, 121, e57 - e69
Gordon S. and Martinez FO., (2010), Immunity, 32, 593 - 604
Murray PJ. et al, (2014), Immunity, 41, 14 - 20
CBP30, a selective CBP/p300 bromodomain inhibitor, suppresses human Th17 responses.
Hammitzsch A. et al, (2015), Proceedings of the National Academy of Sciences of the United States of America, 112, 10768 - 10773
Vengrenyuk Y. et al, (2015), Arteriosclerosis, thrombosis, and vascular biology, 35, 535 - 546
Transcriptional profiling of macrophages derived from monocytes and iPS cells identifies a conserved response to LPS and novel alternative transcription.
Alasoo K. et al, (2015), Scientific reports, 5
Martinez FO. and Gordon S., (2015), Expert review of clinical immunology, 11, 5 - 13
Velecela V. et al, (2014), CARDIOVASCULAR RESEARCH, 103